PRESS RELEASE
26 March 2021

 

Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020

Awards recognize potential of Mogrify’s technology to accelerate the development of regenerative cell and in vivo reprogramming therapies

Cambridge, UK, 26 March 2021: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, was awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at last night’s CambridgeshireLive Business Excellence Awards 2020. The awards recognize the potential of Mogrify’s proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion and the maintenance of cell identity, to accelerate the development of regenerative cell and in vivo reprogramming therapies.

The Company’s technologies, MOGRIFY® and EpiMOGRIFY, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.

Mogrify will use these platforms to engineer therapeutic cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies, and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a cellular therapy and regenerative medicine market estimated to be worth in excess of $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development and collaborations. Since February 2019, Mogrify has raised over $20 million USD in seed and Series A rounds, and $2.5 million USD in grant funding, and has grown to a headcount of over 60 of scientific, operational, and commercial staff.

The CambridgeshireLive Business Excellence Awards are held annually to celebrate businesses and business people in Cambridgeshire and to promote local entrepreneurship and innovation.

Pierre-Louis Joffrin, CDO, Mogrify, said: “We are honored to have been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards. We have an outstanding team of cellular reprogramming experts at Mogrify and this award is testament to their delivery of scientific, commercial and operational excellence.”

For further information on Mogrify, please visit:

https://mogrify.co.uk/about-us/

Notes to Editors

Pierre-Louis Joffrin, Corporate Development Officer, Mogrify

Pierre-Louis Joffrin,
Corporate Development Officer, Mogrify

MOGRIFY® Cellular Conversion Technology

For high-resolution and alternate images please contact Zyme Communications

Mogrify Contacts
Darrin M. Disley, PhD, OBE
Tel: + 44 (0)1223 734154
Email: darrin@mogrify.co.uk

Zyme Communications (media inquiries)
Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: michelle.ricketts@zymecommunications.com

Westwicke, an ICR Company (investor inquiries)
Stephanie Carrington
Tel: +1 (646) 277-1282
Email: stephanie.carrington@icrinc.com

About Mogrify www.mogrify.co.uk

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and EpiMOGRIFY, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors (or small molecules) and optimal culture conditions required to produce any target human cell type from any source human cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to engineer a renewable and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify